Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014
04 Abril 2014 - 3:16PM
Marketwired
Medifocus, Inc. to Be Featured on BNN & Fox Business News
Network on April 6, 2014
BNN to Air at 9:30 AM & 8:00 PM EDT; Fox Business to Air at
5:30 PM EDT
TORONTO, ON--(Marketwired - Apr 4, 2014) - Medifocus, Inc.
(OTCQX: MDFZF) (TSX-VENTURE: MFS) (Medifocus or the Company), a
leader in the development and commercialization of focused
microwave energy to treat cancer and other diseases, announced
today that it will be featured in a 30-minute Life Sciences segment
on BNN & Fox Business News Network on Sunday, April 6,
2014. The segment will air at 9:30 AM and 8:00 PM EDT on
Canada's BNN and at 5:30 PM EDT on U.S. Fox Business News.
The segment discusses the Company's FDA approved,
revenue-generating Prolieve® system, a relatively painless and
effective alternative to drug therapy and certain types of surgical
procedures to treat the symptoms of Benign Prostatic Hyperplasia
(BPH). BPH is a non-cancerous urological disease in which the
prostate enlarges and constricts the urethra. The Prolieve® system
provides a 45-minute in-office treatment that combines microwave
thermotherapy capability with a proprietary balloon compression
technology to both heat the prostate and dilate the prostatic
urethra.
In addition to being aired on April 6th, the excerpt is
available on the BTV website at the following link:
http://www.b-tv.com/i/videos/MedifocusApr14.wmv.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive US and international patent protection: (1) The
Endo-thermotherapy Platform -- a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The U.S. FDA
approved Prolieve Thermodilatation System for the treatment of
Benign Prostatic Hyperplasia ("BPH") was developed based on
Endo-thermotherapy and is currently generating revenue, and (2) The
Adaptive Phased Array (APA) Microwave Focusing Platform -- invented
by MIT, licensed to Medifocus, directs precisely focused microwave
energy at tumor center to induce shrinkage or eradication of tumors
without undue harm to surrounding tissue. The Company's APA 1000
Breast Cancer Treatment System, developed from the APA technology
platform, has received approval from the U.S. FDA and Health Canada
to conduct the pivotal Phase III clinical trials. The Company
believes that these two technology platforms can provide the design
basis for the development of multiple cancer treatment systems for
surface, subsurface and deep seated localized and regional cancers.
Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
Forward-Looking Statements
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of CCTI, Inc., and members of their management
as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking
statements. Important factors currently known to management that
could cause actual results to differ materially from those in
forward-statements include fluctuation of operating results, the
ability to compete successfully and the ability to complete
before-mentioned transactions. The company undertakes no obligation
to update or revise forward-looking statements to reflect changed
assumptions, the statements to reflect changed assumptions, the
occurrence of unanticipated events or changes to future operating
results.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Company Contact: John Mon COO Medifocus, Inc. Tel: 410-290-5734
JohnMon@medifocusinc.com Investor Relations Contact: Robert
Giordano Consulting for Strategic Growth 1 T: 917-327-3938
rgiordanonyc@gmail.com
Medifocus (CE) (USOTC:MDFZF)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Medifocus (CE) (USOTC:MDFZF)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024